Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Alnylam Pharmaceuticals (ALNY) PT Lowered to $116 at Evercore ISI
May 4, 2018 7:51 AM EDTEvercore ISI lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $116.00 (from $118.00) while maintaining a In Line rating.
... MoreAlnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss
May 3, 2018 4:01 PM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.22), $0.25 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $30.15 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More